IOL Chemicals & Pharmaceuticals Ltd Q1 FY2026 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/jw01ilt66jc7b37mezty7kn7.pdf

Key Takeaways


Paracetamol: The Near-Term Growth Engine

Mahajan: "As regarding Paracetamol, the prices are no doubt at a very low level, but the demand is there, not at that level which was during the COVID period. But it is already above the pre-COVID arena area."

Portfolio Diversification & the Non-Ibuprofen Push

Mahajan: "We are setting up a capacity of around 120 tonnes of Minoxidil. And at the peak level, we are expecting a revenue of 50 to 60 from Minoxidil in addition to the intermediate sales."

Export Strategy & Regulatory Pathway

Khanna: "Actually, the current situation of export and domestic is 75% approximately and 25% export. And we are targeting to increase the export to 40% of total revenue in the coming two years."

Margins: The 14%-15% Path

Singh: "See, this is like we are having very clear cut and focus, vision and we are just going all those, our strategies are just getting through. So, we are pretty sure that we will be having it. It is a matter of sometime only."

Capex, Capacity & the Next Growth Phase


Guidance & Commitments

CommitmentSpecificsTimeline
Paracetamol capacity utilizationIncrease from 34% to 60%Q3 FY26
Paracetamol capacity utilizationReach optimum levelNext financial year (FY27)
Consolidated EBITDA marginAchieve 14% to 15%FY26 (full year)
Chemical segment EBITDA margin5% to 6%FY26
Revenue growth10% growth over last yearFY26
Top-line₹600 crores, or very closeFY26
Ibuprofen + non-Ibuprofen revenue₹2,000 croresNext two years
Non-Ibuprofen peak revenue₹900 to ₹1,000 crores2-3 years
Export share of total revenue40% (from 25% currently)Coming two years
Minoxidil facility completionUnit 9B operationalQ3 FY26
Minoxidil peak revenue₹50 to ₹60 crores plus intermediate salesAt peak utilization (undated)
Annual capex₹150 to ₹200 croresFY26
EU GMP auditPlannedNovember

Key Metrics

MetricQ1 FY26
Revenue from operations₹552 cr, 9.8% YoY growth from ₹502 cr in Q1 FY25
EBITDA₹69.5 cr, 19.5% YoY growth from ₹58.2 cr in Q1 FY25
EBITDA margin12.4%, improvement of 102 bps YoY
Profit after tax₹34 cr, 14.4% YoY increase from ₹29.7 cr in Q1 FY25
Cash PAT₹55 cr, over 16% YoY growth from ₹47 cr in Q1 FY25
Revenue growth guidance for FY2610% growth from FY25
Blended EBITDA margin guidance14% to 15%
Chemical segment EBITDA margin guidance for FY265% to 6%
Ibuprofen and non-Ibuprofen segment revenue target₹2,000 cr in the next two years
Non-Ibuprofen API revenue share34% of total API revenue (per an analyst's math)
Non-Ibuprofen API peak revenue target₹900 cr to ₹1,000 cr in 2–3 years, from current ~₹500 cr
Export revenue share25% of total revenue, targeting 40% in two years
Paracetamol plant capacity utilization34% in Q1, expected to reach 60% by Q3 FY26
Metformin capacity utilizationmore than 90%
CAPEX plan for FY26₹150 cr to ₹200 cr